Skip to content
Yog Pharma
Central nervous systemAntiepileptic (sodium channel blocker)

Lamotrigine is an antiepileptic (sodium channel blocker) indicated for epilepsy and maintenance treatment of bipolar I disorder. We supply it to US manufacturers of tablets, chewable dispersible tablets, orally disintegrating tablets and extended-release tablets.

CAS84057-84-1256.1 g/molC9H7Cl2N5
2D structure of Lamotrigine.

Data from PubChem (CID 3878) and FDA’s substance registry

CAS number

84057-84-1

Molecular formula

C9H7Cl2N5

Molecular weight

256.1g/mol

FDA UNII

IUPAC name

6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine

InChIKey

PYZRQGJRPPTADH-UHFFFAOYSA-N

Appearance
White to pale cream-colored powder.
Solubility
Very slightly soluble in water (0.17 mg/mL at 25 °C) and slightly soluble in 0.1 M hydrochloric acid (4.1 mg/mL at 25 °C).

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Particle size matters most for orally disintegrating, chewable and extended-release products.

On the US market

Reference product
LamictalNDA 020241
Approved ANDAs
37 with a marketed product
Approved forms and strengths
  • Extended-release tablet 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, 300 mg
  • Tablet 2 mg to 250 mg, in 8 strengths
  • Orally disintegrating tablet 25 mg, 50 mg, 100 mg, 200 mg
  • Tablet for oral suspension 2 mg, 5 mg, 25 mg

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com